4.7 Article

Identification of immunogenic polypeptides from a Mycoplasma hyopneumoniae genome library by phage display

期刊

APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
卷 80, 期 3, 页码 447-458

出版社

SPRINGER
DOI: 10.1007/s00253-008-1576-1

关键词

phage display; mycoplasma; screening methods; open reading frame enrichment

向作者/读者索取更多资源

The identification of immunogenic polypeptides of pathogens is helpful for the development of diagnostic assays and therapeutic applications like vaccines. Routinely, these proteins are identified by two-dimensional polyacrylamide gel electrophoresis and Western blot using convalescent serum, followed by mass spectrometry. This technology, however, is limited, because low or differentially expressed proteins, e.g. dependent on pathogen-host interaction, cannot be identified. In this work, we developed and improved a M13 genomic phage display-based method for the selection of immunogenic polypeptides of Mycoplasma hyopneumoniae, a pathogen causing porcine enzootic pneumonia. The fragmented genome of M. hyopneumoniae was cloned into a phage display vector, and the genomic library was packaged using the helperphage Hyperphage to enrich open reading frames (ORFs). Afterwards, the phage display library was screened by panning using convalescent serum. The analysis of individual phage clones resulted in the identification of five genes encoding immunogenic proteins, only two of which had been previously identified and described as immunogenic. This M13 genomic phage display, directly combining ORF enrichment and the presentation of the corresponding polypeptide on the phage surface, complements proteome-based methods for the identification of immunogenic polypeptides and is particularly well suited for the use in mycoplasma species.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Biochemistry & Molecular Biology

Antibody display technologies: selecting the cream of the crop

Bernhard Valldorf, Steffen C. Hinz, Giulio Russo, Lukas Pekar, Laura Mohr, Janina Klemm, Achim Doerner, Simon Krah, Michael Hust, Stefan Zielonka

Summary: Antibody display technologies have enabled the successful isolation of antigen-specific antibodies with therapeutic potential, with genotype-phenotype coupling being a key feature. While phage display is the most established system, newer technologies like mammalian display have also matured in recent years.

BIOLOGICAL CHEMISTRY (2022)

Article Gastroenterology & Hepatology

Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis

Richard Taubert, Bastian Engel, Jana Diestelhorst, Katharina L. Hupa-Breier, Patrick Behrendt, Niklas T. Baerlecken, Kurt-Wolfram Suehs, Maciej K. Janik, Kalliopi Zachou, Marcial Sebode, Christoph Schramm, Maria-Carlota Londono, Sarah Habes, Ye H. Oo, Claudine Lalanne, Simon Pape, Maren Schubert, Michael Hust, Stefan Duebel, Mario Thevis, Danny Jonigk, Julia Beimdiek, Falk F. R. Buettner, Joost P. H. Drenth, Luigi Muratori, David H. Adams, Jessica K. Dyson, Amedee Renand, Isabel Graupera, Ansgar W. Lohse, George N. Dalekos, Piotr Milkiewicz, Martin Stangel, Benjamin Maasoumy, Torsten Witte, Heiner Wedemeyer, Michael P. Manns, Elmar Jaeckel

Summary: This study identified more accurate autoantibodies for diagnosing autoimmune hepatitis (AIH) using a protein macroarray, which showed higher specificity and sensitivity compared to conventional autoantibodies. These antibodies could be used as promising markers to improve the diagnostic workup of liver diseases, particularly in cases of seronegative AIH.

HEPATOLOGY (2022)

Article Immunology

MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination

Yeonsu Kim, Xiaoyan Zheng, Kathrin Eschke, M. Zeeshan Chaudhry, Federico Bertoglio, Adriana Tomic, Astrid Krmpotic, Markus Hoffmann, Yotam Bar-On, Julia Boehme, Dunja Bruder, Thomas Ebensen, Linda Brunotte, Stephan Ludwig, Martin Messerle, Carlos Guzman, Ofer Mandelboim, Michael Hust, Stefan Poehlmann, Stipan Jonjic, Luka Cicin-Sain

Summary: CMV vectors induce long-term cellular immunity and long-term immune protection against clinically relevant respiratory pathogens.

CELLULAR & MOLECULAR IMMUNOLOGY (2022)

Article Plant Sciences

Removing the major allergen Bra j I from brown mustard (Brassica juncea) by CRISPR/Cas9

Juvenal Assou, Dingbo Zhang, Kristian D. R. Roth, Stephan Steinke, Michael Hust, Thomas Reinard, Traud Winkelmann, Jens Boch

Summary: The study successfully demonstrated the potential of gene editing breeding to alleviate food allergies by removing or mutating the major allergen Bra j I in brown mustard using CRISPR/Cas9 technology.

PLANT JOURNAL (2022)

Article Multidisciplinary Sciences

Immunity to SARS-CoV-2 up to 15 months after infection

Harold Marcotte, Antonio Piralla, Fanglei Zuo, Likun Du, Irene Cassaniti, Hui Wan, Makiko Kumagai-Braesh, Juni Andrell, Elena Percivalle, Jose Camilla Sammartino, Yating Wang, Stelios Vlachiotis, Janine Attevall, Federica Bergami, Alessandro Ferrari, Marta Colaneri, Marco Vecchia, Margherita Sambo, Valentina Zuccaro, Erika Asperges, Raffaele Bruno, Tiberio Oggionni, Federica Meloni, Hassan Abolhassani, Federico Bertoglio, Maren Schubert, Luigi Calzolai, Luca Varani, Michael Hust, Yintong Xue, Lennart Hammarstrom, Fausto Baldanti, Qiang Pan-Hammarstrom

Summary: This study monitored the immune response in COVID-19 patients up to 15 months after symptom onset. It found that the IgG antibody response and plasma neutralizing titers gradually decreased over time but stabilized after 6 months. SARS-CoV-2-specific memory B and T cells persisted in the majority of patients up to 15 months, but there was a significant decrease in specific T cells between 6 and 15 months. Some variants of concern may partially escape the neutralizing activity of plasma antibodies.

ISCIENCE (2022)

Article Medicine, General & Internal

Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant

Maren Schubert, Federico Bertoglio, Stephan Steinke, Philip Alexander Heine, Mario Alberto Ynga-Durand, Henrike Maass, Jose Camilla Sammartino, Irene Cassaniti, Fanglei Zuo, Likun Du, Janin Korn, Marko Milosevic, Esther Veronika Wenzel, Fran Krstanovic, Saskia Polten, Marina Pribanic-Matesic, Ilija Brizic, Fausto Baldanti, Lennart Hammarstrom, Stefan Duebel, Alan Sustic, Harold Marcotte, Monika Strengert, Alen Protic, Antonio Piralla, Qiang Pan-Hammarstroem, Luka Cicin-Sain, Michael Hust

Summary: This study analyzed the binding ability of the Omicron variant to the human receptor and its neutralization efficacy. The results showed weaker binding and complete loss of neutralization against Omicron compared to previous variants. However, booster vaccination increased the antibody levels and partially restored neutralization against Omicron SARS-CoV-2.

BMC MEDICINE (2022)

Article Chemistry, Medicinal

Phage display-based discovery of cyclic peptides against the broad spectrum bacterial anti-virulence target CsrA

Valentin Jakob, Ben G. E. Zoller, Julia Rinkes, Yingwen F. Wu, Alexander Kiefer, Michael Hust, Saskia M. Polten, Andrew J. White, Peta Harvey, Thomas J. Durek, David Craik, Andreas Siebert, Uli Kazmaier, Martin Empting

Summary: Small macrocyclic peptides have potential as new anti-infective drugs, with cyclisation being essential for their activity. Designed disulfide mimetics and a triazole analogue showed activity against different bacterial targets, providing a starting point for medicinal chemistry optimization.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)

Article Multidisciplinary Sciences

Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant

Fanglei Zuo, Hassan Abolhassani, Likun Du, Antonio Piralla, Federico Bertoglio, Leire de Campos-Mata, Hui Wan, Maren Schubert, Irene Cassaniti, Yating Wang, Jose Camilla Sammartino, Rui Sun, Stelios Vlachiotis, Federica Bergami, Makiko Kumagai-Braesch, Juni Andrell, Zhaoxia Zhang, Yintong Xue, Esther Veronika Wenzel, Luigi Calzolai, Luca Varani, Nima Rezaei, Zahra Chavoshzadeh, Fausto Baldanti, Michael Hust, Lennart Hammarstrom, Harold Marcotte, Qiang Pan-Hammarstrom

Summary: This study demonstrates that an mRNA vaccine booster in individuals vaccinated with inactivated vaccines can significantly increase the humoral and cellular immune responses against the virus, including the Omicron variant.

NATURE COMMUNICATIONS (2022)

Article Clinical Neurology

NMDA-receptor-Fc-fusion constructs neutralize anti-NMDA receptor antibodies

Stephan Steinke, Toni Kirmann, Eleonora A. Loi, Jana Nerlich, Iron Weichard, Philipp Kuhn, Torsten Bullmann, Andreas Ritzau-Jost, Filiz Sila Rizalar, Harald Pruess, Volker Haucke, Christian Geis, Michael Hust, Stefan Hallermann

Summary: Researchers developed and validated a construct that can neutralize autoantibodies from patients with NMDAR encephalitis, preventing receptor internalization and memory deficits in a mouse model. This approach offers a promising strategy for fast and specific treatment of NMDAR encephalitis.
Article Multidisciplinary Sciences

Development of an inhibiting antibody against equine interleukin 5 to treat insect bite hypersensitivity of horses

Nora Langreder, Dorina Schaeckermann, Doris Meier, Marlies Becker, Maren Schubert, Stefan Duebel, Thomas Reinard, Stefanie Figge-Wegener, Kristine Rossbach, Wolfgang Baeumer, Simone Ladel, Michael Hust

Summary: Insect bite hypersensitivity (IBH), the most common allergic skin disease in horses, is caused by bites from Culicoides spp. insects, resulting in a type I/IVb allergy involving eosinophil cells. A potential treatment option is the use of a therapeutic antibody targeting equine interleukin 5, the main activator and regulator of eosinophils. Through phage display and in vitro affinity maturation, an antibody named NOL226-2-D10 was developed, showing strong inhibition of interleukin 5 binding and satisfactory producibility. This antibody is a promising candidate for in vivo studies to treat equine IBH.

SCIENTIFIC REPORTS (2023)

Article Cell Biology

Generation of Chimeric Antigen Receptors against Tetraspanin 7

Tom Pieper, Kristian Daniel Ralph Roth, Viktor Glaser, Tobias Riet, Laura Elisa Buitrago-Molina, Maike Hagedorn, Maren Lieber, Michael Hust, Fatih Noyan, Elmar Jaeckel, Matthias Hardtke-Wolenski

Summary: Adoptive transfer of antigen-specific regulatory T cells (Tregs) has shown promising results in treating autoimmune diseases. However, obtaining sufficient antigen-specific Tregs from patients with autoimmune disorders remains challenging. In this study, researchers aimed to generate CARs against TSPAN7, a membrane protein highly expressed on the surface of pancreatic beta cells, using phage display technology. Although the resulting CARs were functional and specifically activated by the target structure, they could not recognize TSPAN7 on the surface of beta cells. This study demonstrates the power of CAR technology in generating antigen-specific T cells and provides new approaches for functional CAR generation.
Letter Health Care Sciences & Services

Heterologous inactivated virus/mRNA vaccination response to BF.7, BQ.1.1, and XBB.1

Fanglei Zuo, Rui Sun, Hassan Abolhassani, Likun Du, Yating Wang, Stelios Vlachiotis, Federico Bertoglio, Maren Schubert, Nima Rezaei, Zahra Chavoshzadeh, Concetta Guerra, Andrea Cavalli, Juni Andrell, Makiko Kumagai-Braesch, Yintong Xue, Yunlong Cao, Michael Hust, Davide F. Robbiani, Xiaoliang Sunney Xie, Lennart Hammarstrom, Harold Marcotte, Qiang Pan-Hammarstrom

LANCET REGIONAL HEALTH-WESTERN PACIFIC (2023)

Article Immunology

Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells

Sebastian Lutz, Katja Klausz, Anca-Maria Albici, Lea Ebinger, Lea Sellmer, Hannah Teipel, Andre Frenzel, Anna Langner, Dorothee Winterberg, Steffen Krohn, Michael Hust, Thomas Schirrmann, Stefan Duebel, Regina Scherliess, Andreas Humpe, Martin Gramatzki, Christian Kellner, Matthias Peipp

Summary: This study successfully activated natural killer cells and induced lysis of lymphoma cells by preparing novel bispecific antibodies. The study also found that co-administration with specific monoclonal antibodies or bispecific T cell engagers enhanced antibody-dependent cell-mediated cytotoxicity and T cell activation. Furthermore, the study proposed a combinatorial approach targeting multiple tumor antigens, which has the potential to optimize antibody cancer therapies.

FRONTIERS IN IMMUNOLOGY (2023)

Article Immunology

CAR-Ts redirected against the Thomsen-Friedenreich antigen CD176 mediate specific elimination of malignant cells from leukemia and solid tumors

Anna Christina Dragon, Luca Marie Beermann, Melina Umland, Agnes Bonifacius, Chiara Malinconico, Louisa Ruhl, Patrik Kehler, Johanna Gellert, Lisa Weiss, Sarah Mayer-Hain, Katharina Zimmermann, Sebastian Riese, Felicitas Thol, Gernot Beutel, Britta Maecker-Kolhoff, Fumiichiro Yamamoto, Rainer Blasczyk, Axel Schambach, Michael Hust, Michael Hudecek, Britta Eiz-Vesper

Summary: CD176-CAR-T cells specifically recognize the widely expressed CD176 antigen on cancer cells, providing a promising approach for the treatment of various blood and solid tumors while avoiding on-target/off-tumor cytotoxicity.

FRONTIERS IN IMMUNOLOGY (2023)

Article Immunology

Antibodies to coagulase of Staphylococcus aureus crossreact to Efb and reveal different binding of shared fibrinogen binding repeats

Federico Bertoglio, Ya-Ping Ko, Sheila Thomas, Liliana Giordano, Francesca Romana Scommegna, Doris Meier, Saskia Polten, Marlies Becker, Srishtee Arora, Michael Hust, Magnus Hook, Livia Visai

Summary: Staphylococcus aureus pathogenesis is mediated by a variety of virulence factors, including coagulase (Coa) and extracellular fibrinogen-binding protein (Efb) which interact with fibrinogen (Fg). This study describes the selection and characterization of fully human monoclonal antibodies against the C-terminal of Coa, which can also recognize and block the interaction between Coa/Efb and Fg. The discovery of these antibodies provides a novel therapeutic option against S. aureus.

FRONTIERS IN IMMUNOLOGY (2023)

暂无数据